Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-2.2%
$0.01
$0.01
$0.02
$1.10M-0.92416,746 shs389,398 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.86
-2.8%
$0.91
$0.47
$8.39
$4.35M1.31299,961 shs13,716 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$2.17
-1.4%
$3.42
$2.00
$12.11
$3.60M-0.172.57 million shs33,591 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$2.74
-3.9%
$3.63
$1.31
$6.20
$4.67M-0.7957,929 shs7,272 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-2.15%-6.19%-9.00%+1.11%-5.01%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-1.16%-8.07%-9.04%+40.16%+360.42%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-1.36%-22.50%-33.44%-39.55%-80.48%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-3.86%-2.49%-45.85%+8.30%-26.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.756 of 5 stars
0.03.00.04.80.60.00.0
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.6631 of 5 stars
0.05.00.00.01.10.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.09N/AN/A($2.64) per share0.00
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.71N/AN/A($4.12) per share-0.53
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$11K408.51N/AN/A$1.29 per share2.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.86N/AN/AN/A-123.06%-94.28%N/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$6.26MN/A0.00N/AN/AN/A-260.91%8/16/2025 (Estimated)
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.68M-$2.54N/AN/AN/A-169.34%-124.28%8/13/2025 (Estimated)

Latest EVFM, MTNB, TCRT, and QLGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/21/2025Q1 2025
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A-$1.82N/A-$1.82N/AN/A
5/15/2025Q1 2025
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.50-$0.67+$3.83-$0.67N/A$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
1.01
1.01
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A
1.00
1.00

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
27.72%

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
16.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.64 million1.61 millionNot Optionable
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
401.64 million1.38 millionNo Data

Recent News About These Companies

Alaunos Therapeutics Appoints Holger Weis as New CEO
Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0091 0.00 (-2.15%)
As of 08/1/2025 03:37 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$0.86 -0.03 (-2.84%)
Closing price 08/1/2025 03:55 PM Eastern
Extended Trading
$0.86 0.00 (0.00%)
As of 08/1/2025 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$2.17 -0.03 (-1.36%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.17 +0.00 (+0.23%)
As of 08/1/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Alaunos Therapeutics stock logo

Alaunos Therapeutics NASDAQ:TCRT

$2.74 -0.11 (-3.86%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.78 +0.04 (+1.46%)
As of 08/1/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.